[go: up one dir, main page]

PE20010113A1 - Derivados de piperidina utiles como antagonistas ccr5 - Google Patents

Derivados de piperidina utiles como antagonistas ccr5

Info

Publication number
PE20010113A1
PE20010113A1 PE2000000406A PE0004062000A PE20010113A1 PE 20010113 A1 PE20010113 A1 PE 20010113A1 PE 2000000406 A PE2000000406 A PE 2000000406A PE 0004062000 A PE0004062000 A PE 0004062000A PE 20010113 A1 PE20010113 A1 PE 20010113A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
heteroaryl
piperidine derivatives
ccr5 antagonists
Prior art date
Application number
PE2000000406A
Other languages
English (en)
Inventor
Bahige M Baroudy
John W Clader
Hubert B Josien
Mark A Laughlin
Michael W Miller
Susan F Vice
Brian A Mckittrick
Bernard R Neustadt
Anandan Palani
Ruo Steensma
Jayaram R Tagat
Stuart W Mccombie
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20010113A1 publication Critical patent/PE20010113A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIPERIDINA DE FORMULA II, DONDE: Xa ES -C(R13)2-, -C(R13)(R19)-, -C(O)-, -O-, -NH-, -(OR3)-(-C(R13))-, -C(=NOR4)-, (-CR13-)-NR5-CO-ALQUILO C1-C6, ENTRE OTROS; Ra ES R6a-FENILO, R6a-PIRIDILO, R6a-TIOFENILO, R6-NAFTILO; R1 ES H, ALQUILO C1-C6, ALQUENILO C2-C6; R2 ES R7,R8,R9-FENILO, R7,R8,R9-HETEROARILO DE 6 MIEMBROS, R7,R8,R9-N-OXIDO DE HETEROARILO DE 6 MIEMBROS, R10,R11-HETEROARILO DE 5 MIEMBROS, ENTRE OTROS; R3 ES R10-FENILO, PIRIDILO, PIRAZINILO, TIAZOLILO; R4 ES H, ALQUILO C1-C6, FLUORALQUILO C1-C6, CICLOPROPILMETILO, ENTRE OTROS; R5 Y R11 SON H, ALQUILO C1-C6; R6a ES H, HALOGENO, CF3, CN, CF3O, ENTRE OTROS; R6 ES R6a Y CH3SO2; R7 Y R8 SON ALQUILO C1-C6, HALOGENO, NR20R21, OH, CF3, OCH3, O-ACILO, OCF3; R9 ES R7, H, FENILO, NO2, -CN, -CH2F, ENTRE OTROS; R10 ES ALQUILO C1-C6, NH2, R12-FENILO; R12 ES H, ALQUILO C1-C6, CF3, CO2R20, ENTRE OTROS; R13, R14, R15, R16 SON H, ALQUILO C1-C6; R19 ES R6-FENILO, R6-HETEROARILO, R6-NAFTILO, ENTRE OTROS. R19 ES ES R6-FENILO, R6-HETEROARILO, ENTRE OTROS. TAMBIEN SE REFIERE AL USO COMBINADO CON INHIBIDORES DE TRANSCRIPTASA INVERSA NUCLEOSIDICA O NO NUCLEOSIDICA, INHIBIDORES DE PROTEASA. LOS COMPUESTOS SON ANTAGONISTAS CCR5 SELECTIVOS Y PUEDEN SER UTILES EN EL TRATAMIENTO DE VIH, RECHAZO DE TRANSPLANTE DE ORGANOS, ARTRITIS, ARTRITIS REUMATOIDE
PE2000000406A 1999-05-04 2000-05-02 Derivados de piperidina utiles como antagonistas ccr5 PE20010113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30518799A 1999-05-04 1999-05-04

Publications (1)

Publication Number Publication Date
PE20010113A1 true PE20010113A1 (es) 2001-02-05

Family

ID=23179704

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000406A PE20010113A1 (es) 1999-05-04 2000-05-02 Derivados de piperidina utiles como antagonistas ccr5

Country Status (32)

Country Link
EP (2) EP1659111A3 (es)
JP (3) JP3894729B2 (es)
KR (1) KR100439357B1 (es)
CN (2) CN1151131C (es)
AR (1) AR023939A1 (es)
AT (1) ATE299866T1 (es)
AU (2) AU780983B2 (es)
BR (1) BR0010607A (es)
CA (1) CA2371587C (es)
CO (1) CO5170522A1 (es)
CZ (1) CZ301161B6 (es)
DE (1) DE60021371T2 (es)
DK (1) DK1175402T3 (es)
EG (1) EG24533A (es)
ES (1) ES2246233T3 (es)
HK (1) HK1039330B (es)
HU (1) HUP0203528A3 (es)
IL (1) IL145742A0 (es)
MY (1) MY141473A (es)
NO (1) NO322044B1 (es)
NZ (1) NZ514675A (es)
PE (1) PE20010113A1 (es)
PL (1) PL203117B1 (es)
PT (1) PT1175402E (es)
RU (2) RU2266281C2 (es)
SA (1) SA00210270B1 (es)
SI (1) SI1175402T1 (es)
SK (1) SK286968B6 (es)
TR (2) TR200402496T2 (es)
TW (1) TWI283666B (es)
WO (1) WO2000066559A1 (es)
ZA (1) ZA200108867B (es)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
AU2002255947B8 (en) * 2001-03-29 2005-11-17 Schering Corporation CCR5 antagonists useful for treating AIDS
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
NZ530202A (en) 2001-07-02 2005-06-24 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
AR036882A1 (es) * 2001-10-15 2004-10-13 Schering Corp Sintesis de (4-bromofenil)(4-piperidil)metanona-(z)-o-etiloxima y sales
US6818773B2 (en) 2001-10-15 2004-11-16 Schering Corporation Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbony)]-4'-methyl-1,4-′bipiperidine
CA2467555A1 (en) * 2001-11-29 2003-08-14 Schering Corporation Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
EP2311818B1 (en) 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
SE0200843D0 (sv) * 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
CN101139343A (zh) * 2002-03-29 2008-03-12 先灵公司 作为ccr5拮抗药的哌啶和哌嗪化合物的合成
US20050245537A1 (en) * 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
WO2004026833A1 (ja) * 2002-09-20 2004-04-01 Takeda Pharmaceutical Company Limited 環状アミン化合物、その製造法および用途
JP2004107298A (ja) * 2002-09-20 2004-04-08 Takeda Chem Ind Ltd ウレア化合物およびその用途
GB0223223D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
CN1744899A (zh) * 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
RU2366655C2 (ru) 2003-03-14 2009-09-10 Оно Фармасьютикал Ко., Лтд. Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
JPWO2004092136A1 (ja) * 2003-04-18 2006-07-06 小野薬品工業株式会社 含窒素複素環化合物およびその用途
EP1619193A4 (en) 2003-04-18 2010-08-11 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
JP2007505951A (ja) * 2003-06-13 2007-03-15 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとしてのキノリルアミド誘導体類
CN1816518A (zh) 2003-07-10 2006-08-09 先灵公司 由3－酮链烷酸酯制备和纯化2－(烷氧基亚烷基)－3－酮链烷酸酯的方法
SE0302956D0 (sv) * 2003-11-07 2003-11-07 Astrazeneca Ab Chemical compounds
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
RU2006132465A (ru) 2004-02-10 2008-03-20 Ф.Хоффманн-Ля Рош Аг (Ch) Модуляторы хемокинового рецептора ccr5
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
EA015517B1 (ru) 2004-04-13 2011-08-30 Инсайт Корпорейшн Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
ES2297727T3 (es) 2004-06-09 2008-05-01 F. Hoffmann-La Roche Ag Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos.
CN101775013A (zh) 2004-09-13 2010-07-14 小野药品工业株式会社 含氮杂环衍生物及含有其作为活性成分的药物
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
EP1844037A1 (en) * 2005-01-20 2007-10-17 Pfizer Limited Chemical compounds
US7868006B2 (en) * 2005-02-16 2011-01-11 Schering Corporation Heterocyclic substituted piperazines with CXCR3 antagonist activity
PE20061012A1 (es) * 2005-02-23 2006-10-03 Schering Corp Derivados piperidinil piperazina como inhibidores de receptores quiomicina
MX2007010257A (es) * 2005-02-23 2007-09-11 Schering Corp Derivados de piperidinil piperidina utiles como inhibidores de receptores de quimiocinas.
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JPWO2006129679A1 (ja) 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
ES2397418T3 (es) 2005-07-21 2013-03-06 Astrazeneca Ab Derivados de piperidina
AU2006303368B2 (en) 2005-10-19 2011-05-26 F. Hoffmann-La Roche Ag Non-Nucleoside Reverse Transcriptase Inhibitors
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CA2644368A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP2059515A2 (en) * 2006-04-12 2009-05-20 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
RU2457209C2 (ru) 2006-04-21 2012-07-27 Новартис Аг Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
CN101501002B (zh) 2006-08-16 2012-06-27 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
DK2104535T3 (da) 2007-01-10 2011-04-04 Irm Llc Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
AU2008233930A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
BRPI0811562A2 (pt) 2007-05-07 2014-12-09 Novartis Ag Compostos orgânicos
PT2444120T (pt) 2007-12-10 2018-01-03 Novartis Ag Análogos da amilorida espirocíclicos como bloqueadores de enac
WO2009111218A2 (en) * 2008-02-29 2009-09-11 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2009150137A2 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
PE20170003A1 (es) 2009-08-17 2017-03-15 Intellikine Llc Compuestos heterociclicos y usos de los mismos
IN2012DN01453A (es) 2009-08-20 2015-06-05 Novartis Ag
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
DK2593452T3 (en) 2010-07-14 2017-04-24 Novartis Ag Heterocyclic compounds as IP receptor agonists
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
IN2014KN01075A (es) 2011-11-18 2015-10-09 Heptares Therapeutics Ltd
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
WO2013105066A1 (en) 2012-01-13 2013-07-18 Novartis Ag Salts of an ip receptor agonist
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
JP2016507582A (ja) 2013-02-13 2016-03-10 ノバルティス アーゲー Ｉｐ受容体アゴニスト複素環式化合物
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
EA201691278A1 (ru) 2013-12-19 2017-02-28 Байер Фарма Акциенгезельшафт Замещенные пиперидинил-тетрагидрохинолины
WO2015091415A1 (de) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten
US9624199B2 (en) 2013-12-19 2017-04-18 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174869B1 (en) 2014-07-31 2020-08-19 Novartis AG Combination therapy of a met inhibitor and an egfr inhibitor
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) * 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
MX2021015133A (es) 2019-06-10 2022-01-24 Novartis Ag Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
CR20220060A (es) 2019-08-28 2022-03-01 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
DK0912515T3 (da) * 1996-07-10 2003-03-10 Schering Corp 1,4-Disubstituerede piperidiner som muscarinantagonister
AU6623796A (en) * 1996-07-25 1998-02-20 Terence George Mackay Improvements in or relating to fishing
SK20199A3 (en) * 1996-08-15 2000-03-13 Schering Corp Ether muscarinic antagonists
EP1003514A4 (en) * 1997-07-25 2000-10-11 Merck & Co Inc CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS

Also Published As

Publication number Publication date
RU2005120376A (ru) 2006-12-27
NO20015365D0 (no) 2001-11-02
JP2011219493A (ja) 2011-11-04
AR023939A1 (es) 2002-09-04
HK1039330A1 (en) 2002-04-19
CZ301161B6 (cs) 2009-11-18
IL145742A0 (en) 2002-07-25
JP2006225407A (ja) 2006-08-31
HUP0203528A3 (en) 2003-11-28
TR200402496T2 (tr) 2005-01-24
TWI283666B (en) 2007-07-11
MY141473A (en) 2010-04-30
BR0010607A (pt) 2002-02-13
CN1151131C (zh) 2004-05-26
SK15672001A3 (sk) 2002-06-04
PT1175402E (pt) 2005-11-30
NO322044B1 (no) 2006-08-07
EP1175402B1 (en) 2005-07-20
KR20020019906A (ko) 2002-03-13
EP1659111A3 (en) 2007-05-09
AU4501000A (en) 2000-11-17
CA2371587A1 (en) 2000-11-09
AU2005202358B2 (en) 2008-01-10
JP2002543186A (ja) 2002-12-17
JP3894729B2 (ja) 2007-03-22
DK1175402T3 (da) 2005-11-21
CA2371587C (en) 2005-09-13
HUP0203528A2 (hu) 2003-02-28
SI1175402T1 (en) 2005-10-31
CN1349504A (zh) 2002-05-15
CN1524527A (zh) 2004-09-01
CO5170522A1 (es) 2002-06-27
DE60021371T2 (de) 2006-04-27
ES2246233T3 (es) 2006-02-16
EP1175402A1 (en) 2002-01-30
AU780983B2 (en) 2005-04-28
SK286968B6 (sk) 2009-08-06
WO2000066559A1 (en) 2000-11-09
ZA200108867B (en) 2003-03-26
HK1039330B (en) 2005-12-09
SA00210270B1 (ar) 2006-09-04
EG24533A (en) 2009-08-30
EP1659111A2 (en) 2006-05-24
CZ20013941A3 (cs) 2002-04-17
PL203117B1 (pl) 2009-08-31
RU2266281C2 (ru) 2005-12-20
DE60021371D1 (de) 2005-08-25
NO20015365L (no) 2002-01-03
PL351412A1 (en) 2003-04-22
AU2005202358A1 (en) 2005-06-23
ATE299866T1 (de) 2005-08-15
NZ514675A (en) 2004-05-28
TR200103213T2 (tr) 2002-03-21
KR100439357B1 (ko) 2004-07-07

Similar Documents

Publication Publication Date Title
PE20010113A1 (es) Derivados de piperidina utiles como antagonistas ccr5
PE20010150A1 (es) Derivados de piperazina utiles como antagonistas ccr5
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
PE20020996A1 (es) Antagonistas de ccr5 utiles para el tratamiento del sida
PE20011348A1 (es) Agentes antivirales de imidazopiridina e imidazopimiridina
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
NO920494L (no) Terapeutiske, heterosykliske forbindelser
NO20004624L (no) Benzensulfonamid-derivater og deres anvendelse som medikamenter
PE20200665A1 (es) Compuestos espirociclicos y sus metodos de preparacion y uso
KR930004276A (ko) 치환된 헤테로사이클류
TW326447B (en) Substituted 2-phenylpyridines, intermediates and process for their preparation and application thereof
NO940610L (no) Oksazolidinedionderivater, deres fremstilling og anvendelse
PE20000427A1 (es) Nuevas dihidropirimidinas
AP9901442A0 (en) 4-(2-Keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists.
PE20010807A1 (es) Uso de antagonistas del factor de liberacion de corticotropina y composiciones relacionadas
PE20081775A1 (es) Compuestos macrociclicos como inhibidores del factor viia
PE20020508A1 (es) DERIVADOS DE PIRIDINA COMO INHIBIDORES DE LA ACTIVIDAD DE LA QUINASA IkB ß
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
PE20020228A1 (es) Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa
PE20011068A1 (es) 1,3-pirrolidinas disustituidas
DE3868301D1 (de) 2-(methyl(4-piperidinyl))-1,2,3,4-tetrahydro-9h-pyrido(3,4-b)indolderivate, ihre herstellung und therapeutische verwendung.
ES2105617T3 (es) Derivados de piperacina como antagonistas de 5-ht.
DE60034961D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
WO2005080357A3 (fr) Derives d’oxazole, leur preparation et leur utilisation en therapeutique
PE20020676A1 (es) Compuestos de mutilina como antibacterianos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed